Mebiopharm Co., Ltd
HomeSitemapNotes for UsageInquiry{
Management Philosophy
Business Plan
Company Outline
Research & Development
Transferrin Products
Transferrin Products
@ @
Investor Relations

 IR News
13/06/07 Announcement of Delisting and Arrangement of Shares
13/05/10 Announcement of Resolution in Extraordinary Shareholdersf Meeting and Applying Delisting from TOKYO PRO Market
13/04/25 Announcement of Extraordinary Shareholdersf Meeting for Applying Delisting from TOKYO PRO Market
13/03/27 Announcement of Applying for Delisting from TOKYO PRO Market
13/02/12 Announcement of Developing Contrast Agent Using Nano-particle for Ultrasound Contrast
12/06/01 Starting a Clinical Study for Pancreatic Cancer
12/03/26 Replacement of Accounting Auditor (PDF in Japanese)
12/02/20 Joint Venture Establishment in Sri Lanka
11/12/07 Joint press conference on a joint venture in Sri Lanka(pdf in Japanese)
11/12/07 Announcement of establishing a joint venture in Sri Lanka (pdf in Japanese)
11/09/02 Mebiopharm analyst report is publised by Phillip Securities Ltd.
11/07/15 Mebiopharm applied for listing on TOKYO AIM
 Stock Information
As of 31th March, 2015@
Number of shares issued 3,275,800
1 unit of shares 100
Number of Shareholders 35
Handling Office

Corporate Strategy Office

Mebiopharm Co., Ltd.

ARK Hills Executive Tower 8th Floor
1-14-5, Akasaka, Minato-ku, Tokyo, 107-0052

 Other Information

Copyright© 2011 Mebiopharm Co., Ltd.@All Rights Reserved.